Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ

Molecular and Cellular Biology

Volumn 33, Issue 7, 2013, Pages 1303-1316

  Alex, Sheril ^a   Lange, Katja ^a   Amolo, Tom ^a   Grinstead, Jeffrey S ^b,c   Haakonsson, Anders K ^d   Szalowska, Ewa ^a   Koppen, Arjen ^e   Mudde, Karin ^a   Haenen, Daniëlle ^a   Al Lahham, Sa'ad ^f   Roelofsen, Han ^f   Houtman, René ^g   van der Burg, Bart ^h   Mandrup, Susanne ^d   Bonvin, Alexandre M J J ^b   Kalkhoven, Eric ^e   Müller, Michael ^a,i   Hooiveld, Guido J ^a,i   Kerstena, Sander ^a,i  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF PUGET SOUND   (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g PamGene International BV   (Netherlands)

^h BIODETECTION SYSTEMS B V   (Netherlands)

ⁱ TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; INULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL STRAIN HT29; COLON; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEEDING; FERMENTATION; GENE ACTIVATION; GENE CONTROL; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS;

3T3-L1 CELLS; ADENOCARCINOMA; ADIPOGENESIS; ANGIOPOIETINS; ANIMALS; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; FATTY ACIDS, VOLATILE; HT29 CELLS; HUMANS; INULIN; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84875258449     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00858-12     Document Type: Article

References (69)

1. Sekirov I, Russell SL, Antunes LC, Finlay BB. 2010. Gut microbiota in health and disease. Physiol. Rev. 90:859-904.
2. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 101:15718-15723.
3. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. 2007. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. U. S. A. 104:979-984.
4. Lichtenstein L, Kersten S. 2010. Modulation of plasma TG lipolysis by Angiopoietin-like proteins and GPIHBP1. Biochim. Biophys. Acta 1801: 415-420.
5. Yoshida K, Shimizugawa T, Ono M, Furukawa H. 2002. Angiopoietinlike protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43:1770-1772.
6. Ge H, Yang G, Yu X, Pourbahrami T, Li C. 2004. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. J. Lipid Res. 45:2071-2079.
7. Koster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE, Li D, Qiu Y, Fraser CC, Yang DD, Heuer JG, Jaskunas SR, Eacho P. 2005. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146:4943-4950.
8. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Muller M, Kersten S. 2006. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281:934-944.
9. Xu A, Lam MC, Chan KW, Wang Y, Zhang J, Hoo RL, Xu JY, Chen B, Chow WS, Tso AW, Lam KS. 2005. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. U. S. A. 102:6086-6091.
10. Yu X, Burgess SC, Ge H, Wong KK, Nassem RH, Garry DJ, Sherry AD, Malloy CR, Berger JP, Li C. 2005. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl. Acad. Sci. U. S. A. 102:1767-1772.
11. Georgiadi A, Lichtenstein L, Degenhardt T, Boekschoten MV, van Bilsen M, Desvergne B, Muller M, Kersten S. 2010. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferatoractivated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ. Res. 106:1712-1721.
12. Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, He Y, Qi L, Koster A, Tamsma JT, Tan NS, Muller M, Kersten S. 2010. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 12:580-592.
13. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W. 2000. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferatoractivated receptor target gene. J. Biol. Chem. 275:28488-28493.
14. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, Friedman JM, Holmes WE, Spiegelman BM. 2000. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20:5343-5349.
15. Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M. 2007. Genome-wide analysis of PPARalpha activation in murine small intestine. Physiol. Genomics 30:192-204.
16. Staiger H, Haas C, Machann J, Werner R, Weisser M, Schick F, Machicao F, Stefan N, Fritsche A, Haring HU. 2009. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 58:579-589.
17. Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HF, Hesselink MK, Schrauwen P, Muller M. 2009. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29:969-974.
18. Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F, Nicolucci A, Tognoni G, Copetti M, Valanzano R, Veschi S, Mariani-Costantini R, Palasciano G, Schoonjans K, Auwerx J, Moschetta A. 2010. The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 138:636-648.
19. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. 2006. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799.
20. Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, Pettersson S, Arulampalam V, Rafter J. 2010. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 5:e13087. doi:10.1371 /journal.pone.0013087.
21. Siersbaek MS, Loft A, Aagaard MM, Nielsen R, Schmidt SF, Petrovic N, Nedergaard J, Mandrup S. 2012. Genome-wide profiling of peroxisome proliferator-activated receptor gamma in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression. Mol. Cell. Biol. 32:3452-3463.
22. Gijsbers L, Man HY, Kloet SK, de Haan LH, Keijer J, Rietjens IM, van der Burg B, Aarts JM. 2011. Stable reporter cell lines for peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated modulation of gene expression. Anal. Biochem. 414:77-83.
23. Sonneveld E, Riteco JA, Jansen HJ, Pieterse B, Brouwer A, Schoonen WG, van der Burg B. 2006. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 89:173-187.
24. Sonneveld E, Jansen HJ, Riteco JA, Brouwer A, van der Burg B. 2005. Development of androgen-and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol. Sci. 83:136-148.
25. Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E. 2009. Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. Mol. Cell. Proteomics 8:2212-2226.
26. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80. doi:10.1186/gb-2004-5-10-r80.
27. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
28. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. 2005. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33:e175. doi:10.1093/nar/gni179.
29. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C. 2007. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol. Pharmacol. 71:398-406.
30. Dominguez C, Boelens R, Bonvin AM. 2003. HADDOCK: a proteinprotein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125:1731-1737.
31. Malapaka RR, Khoo S, Zhang J, Choi JH, Zhou XE, Xu Y, Gong Y, Li J, Yong EL, Chalmers MJ, Chang L, Resau JH, Griffin PR, Chen YE, Xu HE. 2012. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J. Biol. Chem. 287:183-195.
32. de Vries SJ, van Dijk M, Bonvin AM. 2010. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5:883-897.
33. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
34. Jorgensen WL, Tirado-Rives J. 1988. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 110:1657-1666.
35. Macfarlane GT, Gibson GR, Cummings JH. 1992. Comparison of fermentation reactions in different regions of the human colon. J. Appl. Bacteriol. 72:57-64.
36. Boffa LC, Vidali G, Mann RS, Allfrey VG. 1978. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J. Biol. Chem. 253: 3364-3366.
37. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. 2008. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem. 19:587-593.
38. Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, Glass CK. 2010. Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat. Med. 16:313-318.
39. Han X, Benight N, Osuntokun B, Loesch K, Frank SJ, Denson LA. 2007. Tumour necrosis factor alpha blockade induces an antiinflammatory growth hormone signalling pathway in experimental colitis. Gut 56:73-81.
40. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. 2009. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Digest. Dis. Sci. 54:255-263.
41. Narravula S, Colgan SP. 2001. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J. Immunol. 166:7543-7548.
42. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. 2002. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50:658-664.
43. Wang JB, Qi LL, Zheng SD, Wang HZ, Wu TX. 2009. Curcumin suppresses PPARdelta expression and related genes in HT-29 cells. World J. Gastroenterol. 15:1346-1352.
44. Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Muller-Brusselbach S, Muller R. 2010. Transcriptional profiling identifies functional interactions of TGF beta and PPAR beta/delta signaling: synergistic induction of ANGPTL4 transcription. J. Biol. Chem. 285: 29469-29479.
45. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Muller M, Kersten S. 2004. The direct peroxisome proliferator-activated receptor target fastinginduced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J. Biol. Chem. 279:34411-34420.
46. Camirand A, Marie V, Rabelo R, Silva JE. 1998. Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle. Endocrinology 139:428-431.
47. Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N. 2007. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 27: 1276-1282.
48. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM, Harris RA. 1999. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 48:1593-1599.
49. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ. 2006. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55: 1104-1113.
50. Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS. 2005. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm. Bowel Dis. 11:231-243.
51. Higgins LS, Depaoli AM. 2010. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am. J. Clin. Nutr. 91:267S-272S.
52. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. 2005. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 19:453-461.
53. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN. 2005. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J. Biol. Chem. 280:13600-13605.
54. Rakhshandehroo M, Knoch B, Muller M, Kersten S. 2010. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010: 612089. doi:10.1155/2010/612089.
55. Kinoshita M, Suzuki Y, Saito Y. 2002. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem. Biophys. Res. Commun. 293:827-831.
56. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. 2007. Involvement of different nuclear hormone receptors in butyratemediated inhibition of inducible NF kappa B signalling. Mol. Immunol. 44:3625-3632.
57. Georgiadi A, Kersten S. 2012. Mechanisms of gene regulation by fatty acids. Adv. Nutr. 3:127-134.
58. Bugaut M, Bentejac M. 1993. Biological effects of short-chain fatty acids in nonruminant mammals. Annu. Rev. Nutr. 13:217-241.
59. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. 1987. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221-1227.
60. Dai Y, Wang WH. 2010. Peroxisome proliferator-activated receptor gamma and colorectal cancer. World J. Gastrointest. Oncol. 2:159-164.
61. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. 2006. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-1349.
62. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARgamma and RelA. Nat. Immunol. 5:104-112.
63. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. 1999. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Investig. 104:383-389.
64. Meijer K, de Vos P, Priebe MG. 2010. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr. Opin. Clin. Nutr. Metab. Care 13:715-721.
65. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 2008. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 27:104-119.
66. Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, Lam CR, Yau YH, Tan CK, Huang RL, Tan SM, Tang MB, Ding JL, Kersten S, Tan NS. 2010. Angiopoietin-like 4 interacts with integrins beta1 and beta5 to modulate keratinocyte migration. Am. J. Pathol. 177:2791-2803.
67. Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, Tan CK, Huang RL, Sze SK, Tang MB, Ding JL, Kersten S, Tan NS. 2010. Angiopoietinlike 4 interacts with matrix proteins to modulate wound healing. J. Biol. Chem. 285:32999-33009.
68. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. 2006. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. U. S. A. 103:17450-17455.
69. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB. 2002. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415:813-817.